127 related articles for article (PubMed ID: 25854936)
1. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
2. Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy.
Debiasi M; Hehnemann M; Garicochea B
Sao Paulo Med J; 2010 Dec; 128(6):375-7. PubMed ID: 21308163
[TBL] [Abstract][Full Text] [Related]
3. Time Trend Analysis of Splenectomy for Splenic Marginal Zone Lymphoma: Declining Surgery, Promising Survival.
Yang Z; Liu L; Leng K; Shi G
Ann Surg Oncol; 2023 Nov; 30(12):7206-7216. PubMed ID: 37516724
[TBL] [Abstract][Full Text] [Related]
4. A Rare Case of Factor VII Inhibitor in a Patient Presenting with Primary Splenic Marginal Zone Lymphoma.
Naismith K; Allevato PA; Hamm C
Am J Case Rep; 2021 Sep; 22():e932704. PubMed ID: 34487513
[TBL] [Abstract][Full Text] [Related]
5. Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review.
Guan RY; Tang XR; Huang ZF; Du J; Fu XH; Lu G; Mou WW
Recent Pat Anticancer Drug Discov; 2023 Nov; ():. PubMed ID: 37937574
[TBL] [Abstract][Full Text] [Related]
6. Splenic Marginal Zone Lymphoma in a Patient With Antiphospholipid Syndrome Treated With Rituximab: A Case Report.
Wagle L; Regmi DR; Adhikari S; Basnyat P; Kalla A
Cureus; 2024 Mar; 16(3):e55374. PubMed ID: 38562339
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E; Ferrero S; Bommier C; Drandi D; Ferrante M; Bouabdallah K; Carras S; Gini G; Camus V; Mancuso S; Marcheselli L; Ferrari A; Merli M; Tessoulin B; Stelitano C; Beldjord K; Roti G; Jardin F; Castagnari B; Palombi F; Baseggio L; Traverse-Glehen A; Tripodo C; Liberati AM; Parolini M; Usai S; Patti C; Federico M; Musso M; Ladetto M; Zucca E; Thieblemont C
Haematologica; 2024 Mar; ():. PubMed ID: 38497158
[TBL] [Abstract][Full Text] [Related]
8. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; FoĆ R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
10. Splenic marginal zone lymphoma: from genetics to management.
Arcaini L; Rossi D; Paulli M
Blood; 2016 Apr; 127(17):2072-81. PubMed ID: 26989207
[TBL] [Abstract][Full Text] [Related]
11. Treatment of splenic marginal zone lymphoma.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Vassilakopoulos TP
Best Pract Res Clin Haematol; 2017; 30(1-2):139-148. PubMed ID: 28288709
[TBL] [Abstract][Full Text] [Related]
12. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Roberts AW; Advani RH; Kahl BS; Persky D; Sweetenham JW; Carney DA; Yang J; Busman TB; Enschede SH; Humerickhouse RA; Seymour JF
Br J Haematol; 2015 Sep; 170(5):669-78. PubMed ID: 25942994
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and early treatment outcomes of follicular lymphoma in young adults.
Gangatharan SA; Maganti M; Kuruvilla JG; Kukreti V; Tiedemann RE; Gospodarowicz MK; Hodgson DC; Sun A; Tsang RW; Pintilie M; Crump M
Br J Haematol; 2015 Aug; 170(3):384-90. PubMed ID: 25904266
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.
Kridel R; Xerri L; Gelas-Dore B; Tan K; Feugier P; Vawda A; Canioni D; Farinha P; Boussetta S; Moccia AA; Brice P; Chavez EA; Kyle AH; Scott DW; Sanders AD; Fabiani B; Slack GW; Minchinton AI; Haioun C; Connors JM; Sehn LH; Steidl C; Gascoyne RD; Salles G
Clin Cancer Res; 2015 Aug; 21(15):3428-35. PubMed ID: 25869385
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
Cheung MC; Hay AE; Crump M; Imrie KR; Song Y; Hassan S; Risebrough N; Sussman J; Couban S; MacDonald D; Kukreti V; Kouroukis CT; Baetz T; Szwajcer D; Desjardins P; Shepherd L; Meyer RM; Le A; Chen BE; Mittmann N;
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25868579
[TBL] [Abstract][Full Text] [Related]
17. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
18. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.
Fujimi A; Kamihara Y; Hashimoto A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Ono K; Iyama S; Kato J
Int J Hematol; 2015 Oct; 102(4):471-6. PubMed ID: 25964100
[TBL] [Abstract][Full Text] [Related]
19. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
Goy A; Kalayoglu Besisik S; Drach J; Ramchandren R; Robertson MJ; Avivi I; Rowe JM; Herbrecht R; Van Hoof A; Zhang L; Cicero S; Fu T; Witzig T
Br J Haematol; 2015 Aug; 170(4):496-503. PubMed ID: 25921098
[TBL] [Abstract][Full Text] [Related]
20. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
Radford J; Illidge T; Counsell N; Hancock B; Pettengell R; Johnson P; Wimperis J; Culligan D; Popova B; Smith P; McMillan A; Brownell A; Kruger A; Lister A; Hoskin P; O'Doherty M; Barrington S
N Engl J Med; 2015 Apr; 372(17):1598-607. PubMed ID: 25901426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]